星空加速器官网-outline

Pandect Bioventures provides seed to Series A and later funding to early-stage biotech and pharma companies, along with full management support to help entrepreneurs achieve critical business milestones.

星空加速器官网-outline

Pandect Bioventures identifies transformational healthcare ideas at
the earliest stage, then leverages the knowledge and resources of our rich ecosystem to help build these ideas into successful life science companies.

sgreen安卓安装包

Opportunities are assessed in a rigorous process. Investments include seed, Series A, and later-round funding for startups.

express科学加速器安卓

Access to a 40,000 square foot incubator facility provides fertile ground for growing and cultivating investment opportunities.

798安卓加速器破解下载版

Adobe Photoshop Express 6.8.603 特别版 - QQ前线乐园:今天 · Adobe Photoshop Express，Adobe公司推出的手机图像处理软件，具备专业的图片编辑处理功能，包含几十种特效滤镜效果，支持Raw文件及无缝编辑TIFF图像，即实用又专业的安卓平台图片处理美化工具。 Adobe Photoshop Express：照片编辑器拼贴画制作软件功能： —基本功能：裁切、拉直、旋转、翻转照片、消除 ...

Collaborators

Exclusive relationships with research institutions provide unique access to emerging discoveries, top advisors, intellectual property and research infrastructure.

星空加速器官网-outline

Seed/Series A investments, with participation in later rounds
Established strategic partner network and strong relationships with top biotech venture capital funds
productview express(三维数据查看器) V9.2 中文安装版下载 ...:2021-9-7 · productview express(三维数据查看器) V9.2 中文安装版,productview express是由PTC公司推出的一款十分专业的三维数据查看工具，软件拥有ProductView Lite、productview express、ProductView Adapters等13种模块，用户可众查看零件、测量尺寸 ...
Collaborations with top academic institutions
Financial and technical support for research projects
Funding platforms via our global network

In-licensing and NewCo spinout for later-stage research projects
40,000+ square feet of chemistry/biology incubator space in South San Francisco, the heart of Biotech Bay
State-of-the-art research facilities and equipment supported by technical advisory staff
Onsite CRO services for research and technical support

“The valley of death is moving earlier and earlier in the drug discovery and development cycle — and as a result, promising therapeutic innovations are dying on the vine. We exist to make sure this doesn’t happen.”

— Walter H. Moos, Ph.D., Managing Director, Pandect Bioventures

星空加速器官网-outline

Our management and executives-in-residence bring decades of experience to our investment picks and portfolio growth.

星空加速器官网-outline

Managing Director
Read Bio

星空加速器官网-outline

Managing Director
Read Bio

星空加速器官网-outline

Managing Director
Read Bio

星空加速器官网-outline

Founding Executives in Residence

David Spellmeyer, Ph.D.

Krishna Kodukula, Ph.D.

Robert Wild, Ph.D.

Robert Lutz, Ph.D.

星空加速器官网-outline

Embracing a founder-centric approach, Pandect Bioventures works closely with scientific innovators to advance discoveries rapidly through key value-inflection points.

We review hundreds of investment opportunities per year — each one vetted by a team of principals and executives-in-residence. If merited, opportunities advance through a more detailed due diligence process with subject-area experts.

express加速器破解版

What we look for: 5 pitch essentials for life science entrepreneurs

星空加速器官网-outline

Circle Pharma

In 1Q 2024, we co-invested with The Column Group and Nextech Invest in Circle’s Series B. Circle Pharma is developing a new paradigm for cell permeable macrocyclic peptide discovery based on rational design and synthetic chemistry. The Chair of Circle’s SAB, William G. Kaelin Jr. MD (Harvard Medical School/Dana Farber Cancer Institute), received a Nobel Prize in Medicine and Physiology in 2024. For more information, see: www.circlepharma.com.

798安卓加速器破解下载版
2024

上youtube用什么加速器
Oncology

Area of Focus
Macrocycles

Sgreen加速器官网
Private

Location
South San Francisco, CA

Website
circlepharma

798安卓加速器破解下载版

In 2024, we formed an oncology newco at the ShangPharma incubator with a UCSF co-founder, Alan Ashworth PhD/FRS (President of the UCSF Helen Diller Family Comprehensive Cancer Center and Senior Vice President for Cancer Services with UCSF Health), and led the Seed round in 2Q 2024. Azkarra’s mission is to deliver new oncology therapies to patients based on the team’s deep expertise in DNA Damage Response (DDR). For more information, see: www.azkarrabio.com.

Year Invested
2024

Therapeutic Area
Oncology

798安卓加速器破解下载版
DNA Damage Response

上youtube用什么加速器
Private

Location
South San Francisco, CA

Website
azkarrabio

Valitor

In 2024, we co-led Valitor’s Series A with Berkeley Catalyst Fund. Valitor is a biotech spin-out from the University of California, Berkeley (College of Chemistry and Bioengineering Professors Kevin Healy PhD and David Schaffer PhD, both serial entrepreneurs). Valitor has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacokinetics, target specificity and bioactivity. For more information, see: www.valitorbio.com.

Year Invested
2024

Therapeutic Area
Ophthalmology

Area of Focus
Multi-Valent Protein Conjugates

Status
Private

Location
Berkeley, CA

Website
valitorbio